Displaying 1 through 8 of 71  Next Page >>
Cheryl Gardner joins Parkinson's Institute as the Vice President of Philanthropic Services
Friday, August 31, 2018
Parkinson’s Institute and Clinical Center is excited to welcome Cheryl Gardner as our new Vice President of Philanthropic Services. Cheryl is a seasoned executive who has worked with nonprofit organizations for nearly 20 years, helping them build and increase revenue streams, establish networks, manage resources, raise awareness, and create and
Parkinsonís Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites that May Contribute to Parkinsonís Disease
Friday, June 29, 2018
Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced today a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause Parkinson’s Disease (PD). The interventions, to be developed and identified by Axial, will build on the work of Axial’s scientific Co-founder and
Parkinsonís Institute and Clinical Center Collaborates with Kainos Medicine, Korea for Parkinsonís New Drug Treatment Therapies
Friday, June 29, 2018
Parkinson’s Institute and Clinical Center announced today that it is collaborating with Kainos Medicine, Korea on a new drug therapy. Kainos Medicine recently developed KM-819, which is an innovative new investigational drug based on a novel mode of action that protects dopaminergic neurons from death by inhibiting the function of FAF1 which is known
2018 Drive Toward a Cure Road Rally Puts the Pedal to the Metal Against Parkinsonís
Tuesday, June 19, 2018
“Live in the moment, enjoy the day, make the most of what you have,” once stated Michael J. Fox, celebrated actor and influencer who is currently waging war on Parkinson’s disease. His words could have been the mantra for a band of motorists that recently joined the fight against the insidious condition by raising awareness through the
The Parkinsonís Institute and Clinical Center and Denali Therapeutics announced a partnership to explore endpoints studies of patients with Parkinsonís Disease.
Monday, March 19, 2018
The Institute and Denali aim to support the development of new PD therapeutics by better understanding the potential of new endpoints for clinical studies. Known clinical endpoints for PD can be affected by current standard treatments which, in turn, may confound the measurement of new therapeutics’ impact. The agreement brings together the unique
Exciting partnership to advance precision medicine for LRRK2!
Monday, February 5, 2018
Parkinson's Institute and Clinical Center Collaborates with Merck to Evaluate LRRK2 Kinase Inhibition in Preclinical Model of Parkinson's Disease Sunnyvale, CA January 29, 2018...The Parkinson's Institute and Clinical Center has entered into a collaboration with Merck, known as MSD outside the United States and Canada, to study the effects of LRRK2 kinase
The Parkinson's Institute & Clinical Center and NeuraMetrix, Inc. announced that the Parkinson's Institute & Clinical Center has been elected to the Scientific Advisory Board of NeuraMetrix, Inc.
Monday, November 20, 2017
“The Parkinson’s Institute and Clinical Center is renowned and highly regarded throughout the medical community as a premiere center for excellence in patient care and research,” says Jan Samzelius, CEO, NeuraMetrix. “We welcome Dr. Barlow to our Scientific Advisory Board and are pleased to further our relationship with the
Chrono Therapeutics and the Parkinsonís Institute and Clinical Center announced today the formation of a strategic alliance focused on collaborating on how medicine is delivered to Parkinsonís patients.
Monday, October 23, 2017
The collaboration focuses on understanding the latest methods in delivering needed drugs to Parkinson’s patients transdermally. "This is a unique opportunity for a leading biopharmaceutical company and a world-renowned research institute to combine forces to make a significant impact on Parkinson’s,” said Dr. Carrolee Barlow, CEO
Next Page >>
675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)